Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 53.47

+0.3%

Nov 28 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Biomaven who wrote (3550)	4/23/2001 10:29:48 PM
From: Jibacoa	Read Replies (1) of 52153

Re: Staph.Aureus. As reported recently in Internal Medicine News( April 15,2001),at the recent meeting of the Centers for Disease Control and Prevention Advisory Committee on Immunization Practices in Atlanta,GA. Dr. Gary Horwith, NABI's vice president of clinical and medical affairs commented on NABI's StaphVAX. He said that there are about 9 to 11 million at high risk for S.a. infection in the USA. The vaccine is a bivalent conjugate that contains S.a. capsular types 5 & 8, which comprise more than 80% of the disease causing strains. The vaccine was given to 892 patients with end-stage renal disease who were on hemodialysis. There was a control group of 906 similar patients that received placebo injections. At 6 months there were 17 cases of bacteremia due to S.a. in the placebo group vs. 7 in the StaphVAX group.At ten months the numbers were 26 vs.11 showing a 57% reduction in the vaccinated group. The vaccine efficacy got lower by the end of 1 year. which suggests that boosters should be needed every 8 to 9 months. There were no serious vaccine related side effects, only mild to moderate local reactions which usually subsided in 36 to 48 hrs. The vaccine could potentially be used in other high risk patients, including those scheduled for placement of orthopedic devices, pacemakers, indwelling catheters, drainage shunts, etc. Also one or two weeks prior to CABGs or other prolonged surgical procedures. The vaccine induces antibodies that target multiple sites on the bacterial outer coating and that allows the bacteria to be pagocytized by neutrophils. The targeting of multiple sites makes the development of vaccine resistance less likely because the bacteria would have to undergo multiple genetic mutations. siliconinvestor.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next